Literature DB >> 27896538

Reply to Greenland: A serious misinterpretation of a consistent inverse association of statin use with glioma across 3 case-control studies.

Corinna Seliger1, Christoph R Meier2,3,4, Claudia Becker2, Susan S Jick3, Ulrich Bogdahn5, Peter Hau5, Michael F Leitzmann6.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27896538     DOI: 10.1007/s10654-016-0212-0

Source DB:  PubMed          Journal:  Eur J Epidemiol        ISSN: 0393-2990            Impact factor:   8.082


× No keyword cloud information.
  6 in total

1.  A serious misinterpretation of a consistent inverse association of statin use with glioma across 3 case-control studies.

Authors:  Sander Greenland
Journal:  Eur J Epidemiol       Date:  2016-11-28       Impact factor: 8.082

2.  Statin use and risk of glioma: population-based case-control analysis.

Authors:  Corinna Seliger; Christoph Rudolf Meier; Claudia Becker; Susan Sara Jick; Ulrich Bogdahn; Peter Hau; Michael Fred Leitzmann
Journal:  Eur J Epidemiol       Date:  2016-04-04       Impact factor: 8.082

3.  Disengaging from statistical significance.

Authors:  Kenneth J Rothman
Journal:  Eur J Epidemiol       Date:  2016-06-07       Impact factor: 8.082

4.  HMG CoA reductase inhibitors, NSAIDs and risk of glioma.

Authors:  Jennifer S Ferris; Lucie McCoy; Alfred I Neugut; Margaret Wrensch; Rose Lai
Journal:  Int J Cancer       Date:  2012-04-04       Impact factor: 7.396

5.  Use of statins and risk of glioma: a nationwide case-control study in Denmark.

Authors:  D Gaist; L Andersen; J Hallas; H Toft Sørensen; H D Schrøder; S Friis
Journal:  Br J Cancer       Date:  2013-01-15       Impact factor: 7.640

6.  Statistical tests, P values, confidence intervals, and power: a guide to misinterpretations.

Authors:  Sander Greenland; Stephen J Senn; Kenneth J Rothman; John B Carlin; Charles Poole; Steven N Goodman; Douglas G Altman
Journal:  Eur J Epidemiol       Date:  2016-05-21       Impact factor: 8.082

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.